(19) World Intellectual Property Organization International Bureau

(43) International Publication Date 25 March 2004 (25.03.2004)

PCT

(10) International Publication Number WO 2004/024150 A2

(51) International Patent Classification7: 31/352, A61P 25/24, 25/30.

A61K 31/44,

(21) International Application Number:

PCT/EP2003/010061

(22) International Filing Date:

10 September 2003 (10.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/409,867

10 September 2002 (10.09.2002)

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MARKOU, Athina

[GR/US]; 2284 Cordero Road, Del Mar, CA 92014 (US). KENNY, Paul [IE/US]; 3504 Idlewild Way, San Diego, CA 92117 (US). PATERSON, Neil [GB/US]; 1353 North Vulcan Avenue #D, Encinitas, CA 92024 (US). SEMENOVA, Svetlana [RU/US]; 2312 Hosp Way Apt. 256, Carlsbad, CA 92008 (US).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR TREATING DISORDERS ASSOCIATED WITH mGLU RECEPTORS INCLUDING ADDICTION AND DEPRESSION

Abstract: Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGiuks belonging to at least two different groups. In one embodiment, there are provided methods for treating a disorder associated with mGiu receptors 2, 3, and 5, including administering to a subject in need thereof an effective amount of at least one antagonist w.ich modulates mGluR2, mGluR3, and mGluRS. The disorders treated by the method include, for example, nicotine addiction, cocaine addiction, and depression.

10 • 27525

International Application No PCT/EP 03/10061

						<u> </u>		
A CLASSIF IPC 7	A61K31/44	MATTER A61K31/352	A61P25/2	4 A61P25	/30			
According to	International Patent Clas	sification (IPC) or to both	national classificati	on and IPC				
B. FIELDS SEARCHED								
Minimum do IPC 7	cumentation searched (c A61K	lassification system follow	ed by classification	ı symbols)				
Documentati	on searched other than n	ninimum documentation to	the extent that suc	ch documents are inc	luded in the fields sea	arched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)								
EPO-In	ternal, BIOSI	S, CHEM ABS Da	ata, WPI D	ata, PAJ, E	MBASE			
C. DOCUME	NTS CONSIDERED TO	BE RELEVANT						
Category °	Citation of document, w	ith Indication, where appr	opriate, of the relev	ant passages		Relevant to claim No.		
X	withdrawal metabotrop antagonist BRITISH JO vol. 120, XP00226768 page 1015, page 1017;	URNAL OF PHARM 1997, pages 10	subtype-se receptor MACOLOGY, 015-1020, olumn C olumn	morphine lective		1-5, 10-18, 20,21		
X Furt	ner documents are listed i	in the continuation of box	C.	Patent family	members are listed in	n annex.		
° Special ca	tegories of cited documer	nts:	*	T" later document or	iblished after the Inte	rnational filing date		
"A" document defining the general state of the art which is not considered to be of particular relevance invention." "A" document defining the general state of the art which is not considered to be of particular relevance invention.						the application but eory underlying the .		
filing date cannot be considered novel or cannot be considered to								
which	"L" document which may throw doubts on priority claim(s) or involve an inventive step when the document is taken alone which is died to establish the publication date of another citation or other special reason (as specified) cannot be considered to inventive step when the							
Citation of other special reason (as specialed) Cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such document is combination being obvious to a person skilled								
other means "P" document published prior to the international filing date but later than the priority date claimed "a" document member of the same patent family						·		
Date of the	actual completion of the i	nternational search		Date of mailing of	the international sea	rch-report		
22 January 2004				C 3. 08. 2004				
Name and I	nailing address of the ISA			Authorized office	r			
	NL - 2280 HV Rijsw	040, Tx. 31 651 epo nl,	-	Trifil	ieff-Riolo,	, S		



International Application No
PCT/EP 03/10061

		PC1/EP 03/10061		
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Ozlego.)	Simulation determined with minimal model, where appropriate, of the following management			
X	CHIAMULERA ET AL.: "Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice" NATURE NEUROSCIENCE, vol. 4, no. 9, 2001, pages 873-874,	1-7,9, 20,21		
Y	XP002267684 page 873	6,22,28, 31		
X	SCHULZ ET AL.: "The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats" NEUROPHARMACOLOGY, vol. 41, 2001, pages 1-7, XP002267685 page 6, right-hand column	1-3,8,9, 29		
X	FUNDYTUS ET AL.: "Effect of activity at metabotropic as well as ionotropic (NMDA) glutamate receptors on morphine dependence" BRITISH JOURNAL OF PHARMACOLOGY, vol. 1113, 1994, pages 1215-1220, XP009023674 the whole document	1-5, 10-18, 20,21		
Y	DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, WATERHOUSE ET AL.: "In vivo evaluation of the mGluR antagonist (8H) LY341495" XP002267686 retrieved from BIOSIS Database accession no. PREV200200003805 abstract & WATERHOUSE ET AL.: "In vivo evaluation of the mGluR antagonist (8H) LY341495" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, page 2358,	6,22,28,		



INTERNATIONAL SEARCH REPORT

International application No. PCT/EP 03/10061

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-22,27-31
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22, 27-31

2. claims: 23-26